

Moduladores da Inflamação






Rubor et tumor cum calore et dolore

Celsus, sec I D.C.

Primeira documentação dos sinais típicos da inflamação

**Importância da observação clínica
em vez de medicina baseada em filosofia**



*The inflammatory reaction is
consequence of an excessive
intake by interstitial cells, of
blood...filtering through the
vessel wall*

Virchow, 1871

**Inflamação é decorrente de um processo de
proliferação patológica das células devido
ao extravasamento de nutrientes dos vasos.**

Envolvimento das células



*Finally...there lies outside the
vessel ...a colourless blood
corpuscle*

Cohnheim, 1873

**Corpúsculos sanguíneos eram vistos como
um mecanismo patológico pelo qual a
infecção se espalhava como consequência da
injúria vascular.**

Descrição pioneira da diapedese




The primum movens of the inflammatory reaction is a digestive action...toward the noxious agent

Metchnikoff, 1908

Inflamação como mecanismo celular de defesa, direcionada pelos vasos em vez de um aspecto da patologia por si só.

Fagócitos são protetores e não patogênicos



Inflammation as a triplice response to injury

Lewis, 1927

**Inflamação se caracteriza por eventos vasculares;
mediada por agentes químicos e por axônios**

Reconhecimento da inflamação neurogênica



Inflammation as a multimedated phenomenon, of a pattern type in which all mediators would come and go at the appropriate moment....increasing vascular permeability, attracting leucocytes, producing pain, local edema and necrosis.

Rocha e Silva, 1974

INFLAMAÇÃO




INFLAMAÇÃO

Estereotipia

Mobilização

Substâncias endógenas





INFLAMAÇÃO

Aspectos positivos

Diluição da toxina

Acesso de anticorpos

Transporte de fármacos

Formação de fibrina

Aporte de nutrientes

Estimulação da resposta imune

INFLAMAÇÃO


Aspectos negativos

Lise e morte de tecidos sadios


Edema (aumento de pressão)

Resposta inapropriada

Hipersensibilidade







Estímulo



Molecular

(Regulação de moléculas sinalizadoras e de enzimas)



Celular



Fisiológico

Coagulação

Metabolismo

Vasodilatação

Alteração de matriz extracelular

Angiogênese


Vasopermeação

Atividade neuronal

Espasmo muscular

Dor – Calor - Rubor - Tumor

Integração inflamatória




In vivo rolling can be modeled ex vivo


Inflammation starts with activated endothelium



Control




Inflamed EC






Mastócito



Macrófago



Neutrófilo

Leukocytes roll in vivo


Yang et al, J Exp Med
1999 Dec
20;190(12):1769-82




Intravital microscopy of cremaster muscle venules within 30 min of surgery


PMN Targeting in Acute Inflammation: Variations in Different Vascular Beds

Systemic Venule





Pulmonary Capillary Bed






Início da quimiotaxia



Interação leucócito – endotélio



Preparação do recrutamento celular



Fagocitose




Moduladores

Mediadores (Dale, 1933)

- 1. Mimetização dos sinais da inflamação**
- 2. Sintetizado durante a inflamação**
- 3. Existência de sistemas de síntese e captação**
- 4. Existência de enzimas catalíticas**
- 5. Modulação farmacológica deve mudar a inflamação**
- 6. Sua elevação ou redução deve mudar a inflamação**
- 7. Existência de receptores.**

Histamina






Histamina “in nature”

- **Presence - ubiquitous**
 - **plants**
 - **venoms and stings**
 - **synthesized by bacteria and certain fungi**
 - **found in human tissue**

Distribuição -Histamina


- **unevenly distributed throughout the body**
- **found in various cell types**
 - **mast cells**
 - **basophils - circulating counterpart of the mast cell**
 - **neurons – eg. CNS**
 - **enterochromaffin-like cells (ELC's) in the stomach**
- **tissues**
 - **skin**
 - **lung**
 - **gastrointestinal tract**

Histamina



Aminoethylimidazole

Síntese e Metabolismo



Receptores de Histamina

- types
 - H-1
 - H-2
 - H-3
- histamine stimulates all three
- certain drugs selectively stimulate and block these receptors

Histamina - Efeitos

- **H-1: GI and bronchial smooth muscle contraction**
- **H-2: cardiac stimulation, gastric secretion**
- **H-1 and H-2: dilation of arterioles and veins**
- **H-3:**
 - **Mainly in the CNS**
 - **Preterminal and autoreceptors**

Many organ are be affected by “allergy”

The skin

Urticaria
(hives)



Ativação Seletiva – Bloqueio

- **Ativação**

- **H-1 agonists: 2-methylhistamine, betahistine**
- **H-2 agonist: 4-methylhistamine**

- **Antagonismo**

- **H-1 antagonists: pyrilamine**
- **H-2 antagonists: cimetidine**

Hipersensibilidade Imediata (Tipo I)

Hidrocortisona
Anti-histaminico



12:30 hs



16:30 hs

Many organ are be affected by
“allergy”

The eye

conjunctivitis



Efeitos- Cardiovasculares

- **Vasodilatation in the microcirculation – (H-1 & H-2 – receptors)**
- **Increased “post capillary venule” permeability: H-1 and perhaps H-2 receptors**

Efeitos- Cardiovasculares

- **Lowered systemic blood pressure**
- **Direct effects on the heart (complex)**
 - **H-2: positive inotropic and chronotropic**
 - **H-1: slowed AV conduction**
- **Indirect (reflex) effects on the heart**
 - **positive inotropic and chronotropic effect**
 - **due to decreased blood pressure**

Reação Tríplice

1. Redness at immediate injection site:

Direct vasodilation

2. Larger red area - called a flare:

Due to local axon reflex

3. Wheal: due to increased vessel permeability

Pain, itching (effects on nerves)

Efeitos




- **Extravascular smooth muscle**
 - contraction of bronchial smooth muscle: H-1 mediated
 - contraction of GI smooth muscle: H-1 mediated
- **increased gastric secretion: H-2 mediated**

Sumário

Bronchial contraction	H-1
GI contraction	H-1
Heart	H-2, H-1 (AV node)
Large artery contraction	H-1
Microvessel dilation	H-1 & H-2
Venule permeability	H-1 & H-2 (?)
Gastric acid secretion	H-2
CNS arousal	H-1


Liberação de Histamina

- 1. Immunologic - Hypersensitivity reaction (IgE)**
- 2. Pharmacological (direct release)**
 - **Morphine**
 - **Tubocurarine**
 - **Succinylcholine**
 - **Radiocontrast media**
 - **Carbohydrate plasma expanders**
- 3. Physical stimuli – scratching the skin**

No IgE (in vitro or in IgE $-/-$ mice)	Early phase of IgE-associated immune response	After persistent/repetitive allergen exposure
 Low level surface expression of FcεRI	Low levels of IgE  Enhanced surface expression of FcεRI	High levels of IgE  Greatly enhanced surface expression of FcεRI
Mast cells which have undergone IgE-dependent up-regulation of FcεRI:		
• Can be sensitized to respond to a larger set of different allergens	Increased versatility of immunological effector function	
• Can release mediators and cytokines at lower concentrations of allergen	Increased sensitivity of immunological responsiveness	
• Can release larger amounts of mediators and cytokines in response to allergen	Increased magnitude of immunological effector function	
• Can release certain products (including IL-4) in response to allergen which may not be detectably released at lower levels of FcεRI expression	Change in pattern of mediator/cytokine production; "positive feedback" effects on IgE production	


type I


allergen






Mast cell integrity in rat trachea following OVA challenge





Resting Mast cell




Degranulated mast cell

Efeitos- Endógenos

- 1. Mediator in local and systemic allergic reactions** *(not the only one)*
- 2. Mediator in the tissue response to injury** *(mechanical, thermal, infections, etc.)*
- 3. Mediator of gastric acid secretion**
- 4. Neurotransmitter in the CNS**

When all three stimulators are present, acid secretion is maximally stimulated

Ach, gastrin & histamine act synergistically




Ação não relacionada à inflamação

Antihistaminicos

- **H-1 blockers**
 - **1st Generation or classical (older)**
 - **2nd Generation or non-sedating (newer)**
- **H-2 blockers**
 - **Gastric acid blockers**

Gastric hormones

- ## Histamine



Sir James W. Black

Histamine is found in enterochromaffin-like cells (ECL cells) in the lamina propria of gastric glands

Histamine release is stimulated by:

- gastrin

- acetylcholine

Binds to histamine H_2 receptors and stimulates acid production from parietal cells

Acts **synergistically** with gastrin & Ach

Nobel 1988

Antagonistas Receptores H1

- **1st Generation antihistamines**
 - Cause sedation in therapeutic doses
 - Affect autonomic receptors (cholinergic and adrenergic)
- **2nd Generation antihistamines are sometimes called “non-sedating” antihistamines**

Antagonistas Receptores H1

- 1. Block H-1 receptors competitively**
- 2. Reduce local response to intradermal histamine**
- 3. Antagonize the vasoconstrictor, and to a lesser extent, the vasodilator effects of histamine**

Antagonistas Receptores H1

4. Antagonize histamine-induced bronchospasm

*Does not appreciably affect bronchospasm
associated with anaphylaxis*

5. inhibit gastrointestinal smooth muscle contractions

Antagonistas Receptores H1

6. Some have good local anesthetic activity – *diphenhydramine* may be better than lidocaine
7. 1st Generation antihistamines have some important central effects
 - sedation
 - antimoion sickness
 - excitation – rare in adults; more common in children

Antagonistas Receptores H1

8. other

- Anticholinergic properties - e.g. like atropine
- Alpha adrenergic blockade
- 5-HT receptor blockade

DERIVADOS DO ÁCIDO ARAQUIDÔNICO


Prostaglandinas

- **1930 – Descoberta na vesícula seminal e no plasma humano.**
- **1960 – Demonstração de sua síntese a partir de ácido graxo essencial.**
- **1970 – Drogas similares a aspirina previnem sua ação.**
- **1990 - Múltiplas isoformas de cicloxigenases**



Mecanismo de ação da aspirina

Fosfolipídeo de Membrana



R₁ = PAF?


Ações dos Prostanoides

Relaxamento músculo liso, dor, febre (PGE_2)

Dilatação arteriolar, dor, febre (PGI_2)

Vasoconstrição, ativação de plaquetas (TXA_2)


Broncoconstrição (PGD_2)



AA livre



COX-1 ou COX-2



Transdução de sinal dos receptores para prostanoídes


Tipo	Subtipo	Proteína G	Segundo mensageiro
FP		Gq	IP
IP		Gs, Gq	IP, cAMP ↑
TP	TPa	Gq, Gi	IP, cAMP ↓
	TPb	Gq, Gs	IP, cAMP ↑

Receptores para Prostanóides

Tipo	Subtipo	Proteína G	Segundo mensageiro
DP		Gs	↑ AMPc
EP	EP1	?	↑ Ca
	EP2	Gs	↑ AMPc
	EP4	Gs	↓ AMPc
	EP3	A	↑ AMPc
		B	↑ AMPc
		C	↑ AMPc
		D	↑ ↓ AMPc, IP

Leucotrienos

AA libre



núcleo

citoplasma


FLA₂ c

5-LOX


FLAP

AA


Leucotrienos



núcleo



citoplasma






Table 1. Pharmacologic Actions of Leukotrienes

LTB ₄	Cysteinyl LTs (LTC ₄ , LTD ₄ , LTE ₄ , LTF ₄)
Aggregation of PMNs	Contraction of smooth muscle
Chemotaxis (PMNs)	Constriction of small airways
Chemokinesis of PMNs	Contraction of guinea pig parenchyma
Exudation of plasma	Secretion of mucus
Translocation of calcium	Leakage from postcapillary venules
Stimulation of PLA ₂ (guinea pig lung)	Edema formation
Contraction of human bronchus*	Vasoconstriction
Contraction of guinea pig parenchymal strips*	Coronary arterial constriction
	Stimulation of PLA ₂ (guinea pig lung)
	Antagonism by FPL 55712

TABLE 1 Cells secreting leukotrienes

Cell Type	LTB₄	cystLT	References
Polymorphonuclear leukocytes	+		5
Eosinophils	+	+	32, 35
Mast cells	+	+	4
Alveolar macrophages	+	+	63
Airway epithelial cells	+		64

Table 2. Overview of the CysLT Receptors and Their Antagonists

	CysLT ₁	CysLT ₂
Tissue	Human bronchus Guinea pig trachea Guinea pig gallbladder Rat lung strip	Human pulmonary vein Guinea pig trachea and ileum Sheep trachea and bronchus Ferret trachea
Antagonist	FPL 55712 LY 171 883 ICI 198 615/ICI 204 219 MK-571/MK-679/MK-476 SKF 104 353/SKF 106 203 ONO 1078/SB 205 312 RG 12 525 CGP 45715 BAY x7195 BAY u9773	BAY u9773*
Agonist	LTC ₄ = LTD ₄ ≥ LTE ₄	LTC ₄ ≥ LTD ₄ ≫ LTE ₄




Fig. 1 Cellular sources of cysteinyl-leukotrienes and summary of their effects on airway and inflammatory cells.

Fator Ativador de Plaquetas (PAF)

Fator Ativador de Plaquetas

(1-O-Alquil-2-acil-glicerofosforil-colina)


Origem

Basófilos sensibilizados e desafiados


Fonte

Diversos tipos celulares

Synthesis and breakdown of PAF




Carbon Number of the glycerol "backbone"



R Site where Arachidonic Acid is usually found

PAF Acts Via a Receptor



PAF- Effects

Vasoconstriction/ Vasodilation

Hypotension & Cardiac Depression

Bronchoconstriction

Chemotaxis

Leukocyte- Endothelial Cell Adhesion

PAF- Effects

Leukocyte Emigration


Vascular Leakage

Platelet Aggregation

Stimulates Leukotriene, PAF, Cytokine and

Oxygen Free Radical Release

Efeitos fisiopatológicos




Inflammation

Platelet Activating Factor (PAF)


Cell Activation (inflammatory, endothelial and tissue cells)





Platelet Activating Factor (phospholipase A₂)



* 100 to 10 000 times more potent than histamine



PAF e broncoconstricção



Cytokines

Cytokines



All produced by a variety of cell types:

Cytokines (e.g. $\text{TNF-}\alpha$ / IL-1/ IL-5)

- **cause expression of adhesive proteins on leukocytes / EC's + upregulate receptors**
 - **induce chemoattractant production**
 - **not chemotactic**

Característica funcional

REDUNDÂNCIA




CITOCINAS


EFEITO

Característica funcional

PLEIOTROPISMO



CITOCINA



EFEITOS

Efeitos das citocinas

Autócrino

Paracrino

Endócrino

Citocinas

Pró-inflamatórias

IL-1, TNF, IL-6, IL-11, GMCSF

Anti-inflamatórias

IL-10, IL-1r, IL-4, INFg, IL-12, IL -18

Fator de Necrose Tumoral

Fonte

**Mácrófagos, monocitos; PMN, Eosinófilos, Astrócitos.
(Receptores TNF R-1 e TNF R-2)**

Efeitos

Aumento de aderência de PMN ao endotélio

Permeabilidade vascular


Edema pulmonar


Hipóxia

Insuficiência de múltiplos órgãos e sistemas (I-MOS)

Indução de NO, PGs, LTs, PAF

Trachea





Óxido Nítrico



History of NO discovery (1)

1980, Furchgott and Zawadski reported:

- ACh-induced relaxation of rabbit aorta required the presence of endothelial cells.
- No relaxation in the absence of endothelium.
- Relaxation restored by the addition of exogenous endothelial cells.
- Proposed “Endothelial Derived Relaxing Factor” (EDRF).
- ACh-mediated relaxation was
 - Ca^{2+} dependent
 - mediated via rises in cGMP in the muscle cells
 - Mimicked by NO donors.
- Suggested $\text{NO} \equiv \text{EDRF}$ and was a trans- or inter-cellular signaling molecule.

Óxido Nítrico



NOS: Sintase de óxido nítrico

Constitutiva - dependente Ca^{++}

Neurônios, célula endotelial

Induzida - independente Ca^{++}

Células inflamatórias, endotélio

Nitric Oxide has mixed effects

Second messenger role requires

- low concentrations of NO ($<2\mu\text{M}$)
- occurs usually via guanylate cyclase.

Cytotoxic effects due to a combination of

- Elevated concentration ($>10\mu\text{M}$)
- Interaction with oxygen radicals (e.g. inflammation/reperfusion injury)
- Formation of highly reactive peroxynitrite
- Kinetics of formation (short-term Ca^{2+} regulated vs long-term Ca^{2+} independent).

Properties of NOS isozymes

	Type I	Type II	Type III
Tissue in which first described	Cerebellum (Neuronal)	Immunologically activated Macrophages	Vascular Endothelial Cells
Tissue based terminology	nNOS	mNOS	eNOS
Expression	Constitutive	Inducible	Constitutive
Expression based terminology	cNOS	iNOS	cNOS
Intracellular free Calcium	Regulates	No Effect	Regulates

Tissue Expression of NOS

Type I (nNOS)	Type II (iNOS)	Type III (eNOS)
Neurons	Macrophages	Endothelium
Macula Densa	Cardiomyocytes	GI Interstitial Cells
Photoreceptor Inner segments	Vascular Smooth Muscle	Neurons
Gastric Epithelium	Hepatocytes	
Bronchial Epithelium	Intestinal Epithelium	
Skeletal Muscle	Megakaryocytes	
Endothelium	Keratinocytes	
Mast Cells	Chondrocytes	

NO derived from nNOS

Peripheral Effects (ANS)

NO generated from autonomic Non-Adrenergic, Non-Cholinergic (NANC) nerves acts as a neurotransmitter to relax smooth muscle in:

- Gastrointestinal tract**
- Urogenital tract**
- Airways**

NO derived from eNOS

NO derived from eNOS in vascular endothelial cells contributes to the relaxation of smooth muscle. Effects include:

- **Regulation of blood pressure**
- **Raised tissue perfusion**
 - **Cardiac Perfusion**
 - **Erectile tissue**

Other effects include:

- **Inhibition of platelet adhesion and aggregation:**

NO derived from iNOS

Synthesized *de novo* within selected cell types after exposure to:

- bacterial endotoxins or to
- a range of different cytokines.

Significant in pathophysiological situations e.g.

- Body's defensive response to disease and infection.

NO- efeitos fisiológicos

Regula a pressão sanguínea

Mantém o tônus vasodilatador

Mantém a integridade do endotélio

Inibe proliferação do músculo liso vascular

Previne a interação leucócito~endotélio

Atua como neurotransmissor no SNC

NO- efeitos patofisiológicos

Migração celular

Edema

Atividade tumoricida e bacteriana (M_{ϕ})

Hipotensão choque séptico

Asma

Parasitas intracelulares

Clin Exp Immunol 2002; **129**:4–10

REVIEW

**Nitric oxide: a regulator of mast cell activation and mast
cell-mediated inflammation**

J. W. COLEMAN *Department of Pharmacology and Therapeutics, University of Liverpool, UK*

(Accepted for publication 1 May 2002)





Fig. 4. Inhibitory effects of NO on mast cell activation, mediator release and mast cell dependent vascular inflammatory events.

Initiation of the Acute Inflammatory response



Vamos acordar ??

